Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France. Show more
Location: 65, quai Georges Gorse, Boulogne-Billancourt, 92100, France | Website: https://www.ipsen.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
10.77B
52 Wk Range
$25.11 - $32.25
Previous Close
$30.72
Open
$30.72
Volume
60
Day Range
$30.72 - $30.72
Enterprise Value
2.329B
Cash
679.2M
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.01%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sohonos (Palovarotene) Details Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease | Approved Quarterly sales | |
Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details Alagille syndrome | Approved Quarterly sales | |
Onivyde Details Cancer, Pancreatic cancer, Carcinoma | Approved Quarterly sales | |
Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details Progressive familial intrahepatic cholestasis | Approved Quarterly sales | |
Elafibranor (dual α,δ PPAR agonist) Details Cholestatic Liver Disease, Primary biliary cholangitis | Approved Quarterly sales | |
Tazverik (Tazemetostat ) Details NHL (Non-Hodgkins Lymphoma), R/R FL (Relapsed or Refractory Follicular Lymphoma) and ES (Epithelioid Sarcoma) | Approved Quarterly sales | |
Tazemetostat + rituximab + lenalidomide Details Follicular lymphoma | Phase 3 Data readout | |
Cabometyx + atezolizumab Details Cancer, Prostate cancer | Phase 3 Update | |
Odevixibat (ileal bile acid transport inhibitor) Details Liver disease, Biliary atresia | Phase 3 Update |